Trial watch: Tracing investment in drug development for Alzheimer disease

Nature Reviews Drug Discovery 16, 819 (2017).
doi:10.1038/nrd.2017.169

Authors: Alpha Tom Kodamullil, Firas Zekri, Meemansa Sood, Bastian Hengerer, Luc Canard, Duncan McHale & Martin Hofmann-Apitius
The high failure rates of drug R&D for Alzheimer disease (AD) — and particularly the recent failures of several drugs that target the amyloid cascade in phase III trials — have raised questions about the relative emphasis on particular therapeutic strategies for AD. Here, we

Source: Nature Reviews Drug Discovery - October 23, 2017 Category: Drugs & Pharmacology Authors: Alpha Tom Kodamullil Firas Zekri Meemansa Sood Bastian Hengerer Luc Canard Duncan McHale Martin Hofmann-Apitius Tags: News and Analysis Source Type: research